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Abstract 
Porcine reproductive and respiratory syndrome virus (PRRSV) is prevalent in swine farms 
worldwide and is a major source of economic loss and animal suffering. Rapid genetic variation 
of PRRSV makes it difficult for current vaccines to confer protection against newly emerging 
strains. We recently demonstrated that a novel peptide nanofiber hydrogel (H9e) could act as a 
potent adjuvant for killed H1N1 vaccines. Therefore, the objective of this study was to evaluate 
H9e as an adjuvant for PRRSV modified live virus (MLV) vaccines. Pigs were vaccinated with 
Ingelvac PRRSV MLV with or without H9e adjuvant before being challenged with the VR-2332 
(parental vaccine strain) or MN184A (genetically diverse strain) PRRSV. Pigs vaccinated with 
MLV+H9e had higher levels of circulating vaccine virus. More importantly, pigs vaccinated with 
MLV+H9e had improved protection against challenge by both PRRSV strains, as demonstrated 
by reduced challenge-induced viremia compared with pigs vaccinated with MLV alone.  Pigs 
vaccinated with MLV+H9e had lower frequency of T-regulatory cells and IL-10 production but 
higher frequency of Th/memory cells and IFN-γ secretion than that in pigs vaccinated with MLV 
alone. Taken together, our studies suggest that the peptide nanofiber hydrogel H9e, when 
combined with the PRRSV MLV vaccine, can enhance vaccine efficacy against two different 
PRRSV strains by modulating both host humoral and cellular immune responses. 
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1. Introduction 
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Pork is one of the most widely consumed meats in the world, accounting for more than a third of 
meat production worldwide.  Infectious diseases remain the biggest threat to the pork industry, 
resulting in billions of dollars in economic losses [1]. One particularly devastating disease known 
to lead to the dramatic decline of swine herds and increased pork prices is porcine reproductive 
and respiratory syndrome (PRRS) [1]. Clinical features of PRRS include massive abortion in 
sows and weight loss, respiratory disease, and mortality in young pigs. PRRS outbreaks continue 
to emerge rapidly and with increased virulence; if left untreated, outbreaks will endanger swine 
industries worldwide. 
PRRS is caused by the PRRS virus (PRRSV). Field isolates often differ significantly in 
the degree of virulence and pathogenicity, presumably due to a high degree of genetic variation 
among strains [2]. PRRSV can be broadly divided into two distinct genotypes, Type 1 (European) 
and Type 2 (North American). Each genotype also contains several subtypes, which are also 
genetically diverse and lead to immunity limited to the initial infecting genotype, with only 
partial or no protection from reinfection by other subtypes [3]. Due to genetic diversity and the 
rapid evolution rate of PRRSV, development of a broadly protective PRRSV vaccine is 
challenging, but vaccination remains the most effective way to control PRRS. Several types of 
commercial vaccines, including killed or modified live vaccines, have been widely used [4]. 
Current killed vaccines are largely ineffective in preventing both PRRSV infection and disease, 
so most farms vaccinate their herds with modified live vaccines to control PRRS outbreaks.  
Modified live vaccines are shown to reduce disease caused by genetically similar strains, but 
they provide very limited or no protection against genetically unrelated field isolates [5]. 
Therefore, broad cross-protection against genetically dissimilar PRRSV strains should be the 
main consideration for the design of improved PRRSV vaccines.   
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Adjuvants including oil-in-water emulsions, polymers, and bacterial antigens have been 
tested in combination with modified live vaccines in an effort to reduce the antigenic load and 
improve vaccine efficacy [6, 7]. Results from these studies suggest that addition of adjuvant to 
MLV PRRSV vaccines can lead to increased protection to PRRSV challenge. Peptide hydrogels 
also might be a promising delivery system for vaccines due to their high water content, polymer 
network and reversible sol-gel (solution to gel) formation. Peptide hydrogels have been well 
studied as drug delivery systems, for tissue engineering applications, and in 3-D cell culture and 
show promising results [8, 9]. We recently developed a novel peptide that can form a flexible 
nanofiber hydrogel (H9e) and functions as a potent adjuvant for killed H1N1 influenza vaccines 
[10]. To further characterize the capabilities of the H9e hydrogel, we evaluated H9e as an 
adjuvant for PRRSV MLV vaccines. Results show that the addition of H9e to MLV enhanced 
protection of pigs to both homologous and heterologous strains of PRRSV. Compared with pigs 
vaccinated with MLV alone, animals vaccinated with MLV+H9e developed earlier and more 
robust PRRSV-specific neutralizing antibodies as well as increased PRRSV-specific Th1 
cytokine IFN-γ and reduced immunosuppressive cytokine IL-10. Together, these results suggest 
that PRRS MLV vaccine formulated with H9e adjuvant may increase vaccine efficacy against 
genetically diverse PRRS viruses. 
 
2. Materials and Methods 
2.1. Cells, virus and adjuvant preparation 
MARC-145 cells were maintained in modified Eagle’s medium (MEM) supplemented with 7% 
fetal bovine serum (FBS) containing penicillin (100U/ml) and streptomycin (100 µg/ml) at 37 °C 
with 5% CO2. For virus infection and titration, MEM supplemented with 2% FBS was used. 
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Ingelvac PRRS® modified live virus vaccine (MLV) was purchased from Boehringer Ingelheim 
Vetmedica Inc (St. Joseph, MO). PRRSV MN184A was a kind gift from Dr. Kay Faaberg 
(National Animal Disease Center, USDA-ARS, Ames, IA). PRRSV strains VR-2332 (ATCC, 
Manassas, VA) and MN184A were prepared and titered in MARC-145 cells and stored in 
aliquots at -80 °C until use. H9e peptide was prepared as previously described with a final 
concentration of 17.5 mg/ml [10]. PRRS MLV vaccine was resuspended in 50 ml vaccine diluent, 
provided by the manufacturer, to yield a 2-fold concentrate of vaccine virus. MLV-alone vaccine 
was then mixed 1:1 with vaccine diluent. A solution of 6 mg H9e with 1.2% porcine serum in 
diluent/MEM medium was added 1:1 with 2x MLV to prepare MLV+H9e vaccine. 
 
2.2. Pigs, vaccination and PRRSV challenge 
Thirty-five female/unvaccinated (3 weeks old) Large White-Duroc crossbred PRRSV-free pigs 
were divided into 7 groups (n = 5) and housed in separate pens within the Large Animal 
Research Center (LARC) at Kansas State University. These piglets were confirmed sera-negative 
for antibodies to PRRSV by ELISA and PRRSV-free in serum by RT-PCR. Pigs were 
immunized intramuscularly on day 0 with placebo, PRRS-MLV (1x106 TCID50/ pig), or PRRS-
MLV+H9e (1x106 TCID50 + 6 mg H9e/ pig). Twenty-eight days post vaccination (DPV), the pigs 
were challenged with either homologous PRRSV VR-2332 (1x106 TCID50) or heterologous 
MN184A (5x105 TCID50). Body weight measurements and blood samples were collected weekly 
(0, 7, 14, 21, 28 DPV and 7, 14 DPC). Pigs were also monitored daily for rectal temperature and 
clinical signs after challenge. All pigs were humanly euthanized 15 days post challenge (DPC). 
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All animal experiments were approved by the Institutional Animal Care and Use Committee at 
Kansas State University. 
 
2.3. Analysis of serum virus titer 
Total RNA was extracted from serum and one-step SyBR Green real-time PCR (Bio-Rad, 
Hercules, CA) was performed to evaluate the PRRSV ORF7 expression level as previously 
described [11]. For quantification, total RNA of a known TCID50 of virus was 10-fold serially 
diluted and were used to generate a standard curve. The virus quantities of unknown samples 
were determined by linear extrapolation of the Ct value plotted against the standard curve. 
 
 
2.4. PRRSV-specific and virus neutralizing antibody titration 
PRRSV-specific ELISA antibody titers were measured using the Herdcheck Porcine 
Reproductive and Respiratory Syndrome X3 Antibody Test (IDEXX Laboratories, Westbrook, 
ME) as described by the manufacturer. Virus neutralizing antibody titer in the serum was 
analyzed as previously described [11]. Briefly, serum samples were heat-inactivated and serial 
dilutions were mixed with PRRSV VR-2332 or MN184A viruses. After incubation, the mixtures 
were transferred to MARC-145 cells and incubated for 72 hours. Cytopathic effect (CPE) was 
used to determine the end-point titers that were calculated as the reciprocal of the highest serum 
dilution to neutralize >90% CPE induced by 200 TCID50 of PRRSV in duplicate wells per 
sample.  
 
2.5. Analysis of cytokine responses 
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Pig sera were collected at 7 DPC to evaluate IL-4, IL-8, IL-10, IFN-γ, and TNF-α cytokine 
secretion profiles by ELISA. Procedures were performed as per the manufacturer’s instructions 
(Invitrogen, Carlsbad, CA). Additionally, at necropsy (15 DPC), 106 tracheobronchial lymph 
node (TBLN) mononuclear cells (MNCs) and lung MNCs were restimulated with 200 TCID50 of 
the respective challenge PRRSV similar to that described in Ferrari et al. [12]. Cell culture 
supernatants were analyzed by ELISA for IL-10 cytokine secretion (Invitrogen). 
 
2.6. Flow cytometry analysis 
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood samples by 
Ficoll-Hypaque gradient centrifugation using Histopaque®-1077 (Sigma-Aldrich, St. Louis, MO). 
Flow cytometry analysis was performed to determine different lymphocyte populations based on 
the cell surface marker phenotype: T-helper cells (CD3+CD4+CD8-), cytotoxic T lymphocyte 
(CD3+CD4-CD8+), Th/memory cells (CD3+CD4+CD8+), T-regulatory cells (CD4+FoxP3+CD25+) 
and γδ T cells (CD8+ TcR1N4+). The mouse anti-pig TcR1N4 antibody was purchased from 
VMRD (Pullman, WA), and all other antibodies were purchased from BD Biosciences (San Jose, 
CA). Immuno-stained cells were acquired using a FACS Caliber (BD Biosciences) flow 
cytometer. Frequencies of individual lymphocytes were analyzed by 100,000 events using 
FlowJo software (Tree Star, Inc., Ashland, OR). 
 
2.7. Statistical analysis 
All data were expressed as the mean value of five pigs ± SEM. The differences in the level of 
humoral response, cytokine production and viremia among each group were determined by the 
one-way analysis of variance (ANOVA) followed by post-hoc Tukey’s test using Sigmaplot 11 
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software (Systat Software Inc., San Jose, CA). Differences were considered statistically 
significant when p<0.05. 
 
3. Results 
3.1. H9e adjuvant enhances cross-protection efficacy of MLV to heterologous PRRSV 
infection in pigs 
Our previous studies showed that H9e hydrogel can be a safe, efficacious adjuvant for the killed 
H1N1 swine influenza vaccines, resulting in significantly higher hemagglutination inhibition 
titers and antibody titers to swine influenza than immunization with antigen alone [10]. Since 
H9e acts as a potent adjuvant for killed subunit vaccines, we hypothesized that H9e hydrogels 
could also work as an adjuvant for a modified live PRRS vaccine. 
H9e solution is a free-flowing solution at ambient temperature, and forms an injectable 
hydrogel at physiological conditions. H9e was easily mixed with MLV and showed no virucidal 
effects on the vaccine virus (data not shown). Pigs were vaccinated with Ingelvac PRRS MLV 
vaccine alone (MLV), Ingelvac PRRS MLV vaccine adjuvanted with hydrogel H9e (MLV+H9e), 
or PBS (mock). Twenty-eight days post vaccination (DPV), pigs were subjected to virus 
challenge with low virulence homologous VR-2332 (1 x 106 TCID50/pig) or moderately virulent 
heterologous MN184A (5 x 105 TCID50/pig) strains of PRRSV. The mean body temperature of 
unvaccinated pigs challenged with VR-2332 or MN184A was 0.3 or 1.0 oC higher than 
vaccinated pigs, respectively, with no difference between vaccinated groups (data not shown). 
Interestingly, pigs vaccinated with MLV gained significantly less weight than unvaccinated and 
MLV+H9e vaccinated pigs at 28 DPV (Fig. 1a, b), suggesting that the un-adjuvanted MLV 
vaccine virus may cause sub-clinical disease in pigs.  
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To determine if vaccinated pigs were protected from homologous or heterologous virus 
challenge, titers of circulating virus were measured 7 days post challenge (DPC). We found that 
the pigs vaccinated with MLV+H9e were able to significantly clear both the VR-2332 and 
MN184A strains circulating in the blood 7 days post challenge (7 DPC). Pigs vaccinated with 
MLV alone were able to significantly clear the homologous VR-2332 virus strain (Fig.1c). The 
pigs vaccinated with MLV alone had reduced viral load in the blood after MN184A challenge; 
however, it was not statistically significant from that in the unvaccinated-challenged group of 
pigs (Fig. 1d). Taken together, these results suggest that the addition of H9e adjuvant to PRRSV 
MLV vaccines can enhance protection against genetically distinct stains of PRRSV.   
 
3.2. Pigs vaccinated with MLV+H9e have increased vaccine virus circulation in the blood 
after vaccination 
H9e rapidly forms a gel once it is formulated with MLV. Therefore, we suspect that the H9e 
nanofiber network may act as a scaffold to prolong vaccine virus entry into the blood or enhance 
its replication within the host to enhance the vaccine’s protective effects. To determine if H9e 
adjuvant affects the viral load of the vaccine strain of PRRSV in vaccinated pigs, we measured 
circulating viral load in the serum of all pigs weekly. Interestingly, pigs vaccinated with 
MLV+H9e started to develop significantly higher levels of circulating virus two weeks after 
vaccination and reached an average maximum of 5.5-fold (9,057±402 TCID50 equivalent/ml ) 
higher virus titers than that in pigs vaccinated with MLV alone (1,638± 625 TCID50 equivalent 
/ml) on 21 DPV (Fig. 2a). By 28 DPV, the MLV virus was eliminated from the blood of pigs in 
all groups. Therefore, our results suggest that H9e may act to stabilize the MLV virus within the 
host and thus to increase the exposure of antigen to the host immune system. 
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3.3. H9e-MLV vaccinated pigs show enhanced PRRSV-specific antibodies and PRRSV 
neutralizing antibodies 
To determine whether increased antigen exposure might lead to enhanced humoral and cellular 
immune responses in vaccinated pigs, we first evaluated antibody responses of pigs vaccinated 
with PRRSV MLV in the presence or absence of H9e. Serum samples were analyzed by 
commercial IDEXX PRRSV-specific antibody ELISA. By 14 DPV, 9 out of 10 pigs vaccinated 
with MLV+H9e were positive for PRRSV-specific antibodies (as defined by manufacturer at S/P 
ratio ≥ 0.4), compared with only 5 out of 10 pigs in MLV alone groups (Fig. 2b and 
Supplemental Figure 1). Therefore, these results suggest that addition of H9e adjuvant results in 
the earlier onset of PRRSV antibodies than MLV alone. By 21 DPV, all vaccinated pigs had 
seroconverted to anti-PRRSV antibody positive.  
PRRSV MLV vaccination is characterized by generation of early non-protective 
antibodies specific to the nucleocapsid protein (as measured by IDEXX ELISA) and delayed 
generation of protective virus neutralizing antibodies. To determine if the H9e-mediated 
prolonged viremia affects the production of neutralizing antibodies as well, the PRRSV 
neutralizing antibody titers (VN titers) were analyzed. On 28 DPV, pigs vaccinated with 
MLV+H9e had similar VN titers to both VR-2332 and MN184A as that in pigs vaccinated with 
MLV-alone (Fig.2c). After homologous VR-2332 viral challenge, pigs vaccinated with 
MLV+H9e had significantly higher VN titer to VR-2332 and comparable VN titer to MN184A 
compared with pigs vaccinated with MLV alone (Fig. 2d).  However, all vaccinated pigs 
developed similar levels of VN titers after heterologous MN184A viral challenge (Fig. 2e).  
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Therefore, our results show that the addition of H9e hydrogel adjuvant can induce early on-set 
and enhanced antibody production over vaccinating pigs with MLV alone. 
 
3.4. Pigs vaccinated with MLV+H9e hydrogel have increased pro-inflammatory cytokines 
and reduced immunosuppressive cytokine secretion profiles 
Because we found that H9e can improve the humoral immune responses of pigs to the PRRS 
MLV vaccine, we next assayed the effects of H9e adjuvant on MLV-elicited cytokine profiles. In 
doing so, sera at 7 DPC were analyzed for the presence of IL-4, IL-8, IL-10, IFN-γ and TNF-α. 
As shown in Fig. 3, the levels of IFN-γ, but not TNF-α, in the sera from MLV+H9e vaccinated 
pigs was significantly higher than that in pigs vaccinated with MLV-alone after challenge 
(Fig3a,b). The levels of IL-4 and IL-8 in sera from pigs vaccinated with MLV+H9e were 
significantly higher than that from pigs vaccinated with MLV-alone when the pigs were 
challenged with VR-2332 PRRSV (Fig. 3c, d). Conversely, the secretion of immunosuppressive 
cytokine IL-10 in sera of MLV+H9e vaccinated pigs was reduced compared with that in the 
MLV-alone vaccinated pigs after challenge with both VR-2332 and MN184A (Fig. 3e). IL-10 
expression levels of lung and TBLN MNCs also were analyzed at necropsy (15 DPC). As shown 
in Fig. 3e, after these cells were re-stimulated with either VR-2332 or MN184A in vitro, reduced 
IL-10 cytokine levels were observed in the supernatant of lung and lymph node MNCs of the 
pigs vaccinated with MLV+H9e. Therefore, our results suggest that addition of H9e to MLV 
vaccine alters cytokine expression profiles. 
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3.5. Pigs vaccinated with MLV+H9e display decreased T-regulatory and increased 
Th/memory lymphocyte subpopulations 
To verify if the change in cytokine expression patterns was associated with changes in 
lymphocytes population, the frequencies of T-helper cells, cytotoxic T lymphocyte, Th/memory 
cells, T-regulatory cells and γδ T cells in blood, lung, and lymph nodes were evaluated using 
flow cytometry analysis. As shown in Fig. 4, a significant decrease of the T-regulatory (Treg) 
lymphocyte population (Fig. 4a) and increase of the Th/memory lymphocyte population (Fig. 4b) 
was observed in the blood of pigs vaccinated with MLV+H9e than that in pigs vaccinated with 
MLV alone 4 weeks after vaccination.  The decrease of Treg lymphocyte population and 
increase of Th/memory lymphocyte population were also observed 14 DPC in pigs challenged 
with homologous VR-2332 or heterologous MN184A PRRSV in blood, TBLN, and lung MNC 
samples (Fig. 4c, d). Additionally, we examined Th cells, CTL, γδ T cells and NK cell 
population before and after challenge and found no significant changes in any groups (data not 
shown). 
 
4. Discussion 
 
Current commercial vaccines, both killed virus and modified live, are deficient in protecting 
swine herds from the consistently evolving field isolates of PRRSV [13]. One approach to 
improving PRRSV vaccine efficacy is the addition of immunomodulatory adjuvants including 
water-oil emulsions, aluminum, bacterial components, and polymers to killed or live modified 
PRRSV vaccines [14]. Interestingly, a new class of adjuvants, nanoparticles, has been shown to 
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increase the cross-protection efficacy of killed PRRSV vaccines. In a recent study by Dwivedi et 
al, PLGA nanoparticle-entrapped killed PRRSV vaccine induces a cross-protective immune 
response against heterologous PRRSV challenge via enhanced innate and PRRSV-specific 
adaptive responses [15]. However, further studies are needed to reduce the cost and complexity 
of nanoparticle production before nanoparticle-based vaccines can be widely used as commercial 
products. Some more cost-effect commercial water-in-oil emulsion and polymers adjuvants, such 
as MontanideTM ISA 15A and Gel01 ST, have also been utilized in live modified PRRSV 
vaccines [6].  Deville et al. showed that pigs vaccinated with adjuvanted MLV vaccine 
containing 50% of the antigen load had equivalent protection as pigs vaccinated with full dose of 
vaccine without the adjuvant.  
We recently reported that a biodegradable hydrogel could act as an adjuvant for killed 
swine influenza vaccines [10]. These previous results show that when H9e hydrogel was used in 
place of the supplied adjuvant of commercially available FluSure XP (Zoetis Inc), the H9e-
adjuvanted vaccine led to significantly higher HAI titers and equivalent IgG antibody responses 
than the standard formulation of FluSure. Based on these results, we explored the ability of H9e 
hydrogel to act as an adjuvant for PRRS modified live virus vaccine and here we demonstrated 
that H9e hydrogels enhanced the vaccine’s protective effects for both homologous and 
heterologous PRRSV infection.  
H9e hydrogel forms a biodegradable nanofiber network under physiological conditions 
[16].  Peptide-based nanofiber networks have been shown to aid in the controlled release of 
growth factors, therapeutics, and viruses [17-19]. Therefore, we hypothesized that this nanofiber 
network could create pockets that the vaccine virus could occupy and thus act as an antigen 
depot such that PRRS virus is presented slowly to the host immune system. We show here that 
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the H9e had no virucidal effects and was able to facilitate increased PRRS vaccine virus 
presentation to the host, as shown by enhanced vaccine virus circulation in the blood (Fig. 2a). 
These results suggest high vaccine virus titers in the blood induced by MLV+H9e vaccination 
may facilitate the generation of an early and robust PRRSV immune response and provide better 
protection against genetically diverse strains of PRRSV.  
In addition to high circulating vaccine virus, pigs vaccinated with MLV+H9e had earlier 
on-set of PRRS-specific ELISA antibodies and enhanced neutralizing antibody titers to 
homologous virus. Previous reports have shown that PRRSV-specific antibodies can appear as 
soon as one week post-vaccination or challenge, however seroconversion is often observed 
between 14-21 days post exposure [6, 20]. Our results are consistent with these reports and we 
found that addition of H9e adjuvant reduced the time that most pigs became positive for PRRSV-
specific antibodies (Fig.2b and Supplemental Fig.1). 
In order to gain insight into the immunologic mechanisms employed by the hydrogel 
adjuvant, cytokine expression levels after PRRSV challenge were compared among vaccinated 
groups of pigs. We found that the Th1-related cytokine IFN-γ in the sera of pigs vaccinated with 
MLV+H9e was significantly higher than that of pigs vaccinated with MLV alone after both 
homologous and heterologous challenges (Fig3a, b). IFN-γ is a key cytokine that is associated 
with host cell-mediated immunity (CMI) response, which is secreted by natural killer cells and 
several different T cell subpopulations, and its expression is often decreased by PRRSV infection 
[21, 22]. These studies suggest that decreased IFN-γ expression allows PRRSV to evade the host 
immune response and result in chronic PRRS infections. Interestingly, a recent study using two 
different PRRSV strains reported that systemic enhancement of IFN-γ further activates natural 
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killers and T cell subpopulations creating a positive feedback loop for the rapid clearance of 
PRRSV [23].  
Therefore, the elevated production of IFN-γ observed in the pigs vaccinated with H9e+MLV 
could explain the increased PRRS viral clearance and improved protective immune response we 
observed.  
The expression of inflammatory cytokine IL-8, but not TNF-α, was increased in pigs 
vaccinated with H9e-MLV when pigs were challenged with homologous VR-2332 virus (Fig. 3b 
and d).  In previous studies, low serum IL-8 levels are related to persistent PRRSV infection, and 
elevated IL-8 levels in serum is correlated with the clearance of PRRS virus [24, 25]. Although 
our results also indicated IL-8 may play a role in vaccination-induced clearance of PRRS virus, 
further experimentation is required to fully characterize the ability of H9e adjuvant to modulate 
IL-8 expression levels.  
The Th2-related cytokine IL-4 was increased in the sera of pigs vaccinated with 
MLV+H9e compared with the pigs vaccinated with MLV alone only after homologous VR-2332 
challenge. IL-4 expression has been shown to control macrophage inflammatory activities in the 
pig [26]. While IL-4 expression levels in PRRSV-infected pigs can remain unaltered [27], recent 
studies suggest that natural PRRSV infection can significantly induce the expression of IL-4 [28], 
suggesting that PRRSV-mediated IL-4 induction may be strain dependent. In our hands, the 
increased IL-4 expression after VR-2332 challenge correlated well with enhanced protection of 
pigs vaccinated with MLV+H9e than that of pigs vaccinated with MLV-alone. This indicates IL-
4 may play a positive role in the immune response to PRRSV infection. 
PRRSV infection or vaccination has been shown to induce a strong immunosuppressive 
response characterized by promoting the secretion of IL-10 to antagonize the protective Th1 
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immune response [29, 30]. In our study, we found that the concentrations of IL-10 in the serum 
and tissues of pigs vaccinated with MLV alone were consistently higher than that from pigs 
vaccinated with MLV+H9e (Fig. 3e). IL-10 is mainly produced by a small subpopulation of T 
lymphocytes termed T-regulatory cells [31]. Consistent with IL-10 levels, the frequency of T 
regulatory cells in MLV+H9e vaccinated pigs was dramatically reduced in blood, lung MNCs, 
and TBLNs post infection (Fig. 4c). Therefore, it is likely that the reduced T-regulatory cell 
population and production of IL-10 may contribute to the enhanced Th1 response and efficient 
elimination of PRRSV after challenge in the pigs vaccinated with MLV+H9e. 
CD4+CD8+ T cells, which include T-helper, cytolytic, and memory properties, are a 
major type I IFN-γ cytokine secreting population [32]. In our study, pigs vaccinated with 
MLV+H9e generated significantly higher Th/memory cell populations both before and after 
challenge compared to the unvaccinated and MLV vaccinated pigs. This result is consistent with 
the observation that IFN-γ production is elevated in pigs vaccinated with MLV+H9e. The high 
frequency of functional T memory cells may contribute to rapid recall response for the quick 
elimination of subsequent PRRS virus exposure [33]. The ability of H9e adjuvant to shift MLV 
vaccine from mainly humoral, to a response having both humoral and cell-mediated immune 
responses suggest that CMI may be important for increased vaccine protection potential. Our 
results support the notion that MLV+H9e may act to enhance IFN-γ and reduce IL-10 production 
via increasing Th/memory and decreasing Treg lymphocyte populations, thereby causing a shift 
to a Th1-type immune response to provide a better protection against PRRSV infection. 
 We have previously shown that flexible polymer adjuvants such Montanide™ Gel01 ST 
also can enhance the protective effects of modified live PRRSV vaccines: however, their 
enhanced protective effects are limited to homologous re-infection [11]. Interestingly, it was 
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demonstrated that the addition of Gel01 adjuvant to MLV vaccine could enhance vaccine-
induced antibody-mediated immunity but did not promote a stronger cellular-mediated immunity. 
Furthermore, Gel01 adjuvanted MLV did not show improved efficacy in reducing heterologous 
challenge-induced viremia as compared with MLV alone. Thus, these results and our previous 
work suggest that the vaccine’s ability to generate a cellular-mediated immune response may be 
essential to mediate its cross-protective efficacy against PRRSV infection. 
 
Conclusion 
This study shows that H9e hydrogel as an adjuvant for MLV can improve vaccination-
induced host protection against RRRSV infection by increased circulation of the vaccine virus in 
the blood, enhanced antibody production, and increased CMI responses. We believe that the 
addition of H9e hydrogel adjuvant to existing vaccines is an exciting method to improve PRRS 
live vaccine efficacy. These results encourage us to explore the ability of H9e to work as a 
universal adjuvant for a broad range of animal vaccines. 
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Figure 1 
 
 
Figure 1. H9e adjuvant enhances protection efficacy of MLV to homologous and 
heterologous PRRSV infection in pigs. Pigs (3-week-old) were vaccinated with MLV or 
MVL+H9e and challenged with the VR-2332 or MN184A strain of PRRSV 28 days post 
vaccination. (A, B) Fold body weight gain during the duration of the experiment was determined. 
(C, D) Viral RNA in the serum (TCID50 equivalent /mL) was measured on 7 days post challenge 
(DPC) by RT-PCR. Viremia data are shown as means ± SEM (n=5). Bracketed groups were 
compared and * denotes p <0.05, ** denotes p <0.01. 
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Figure 2 
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Figure 2. Pigs vaccinated with MLV+H9e have increased vaccine virus circulation and 
produce an earlier on-set of PRRSV-specific antibodies. (A) Viral RNA of MLV vaccine 
virus in the serum (TCID50 equivalent /mL) was determined by RT-PCR weekly after vaccination 
with MLV, or MLV+H9e. Data were shown as mean ± SEM (n=5) ** p <0.01. (B) Serum from 
vaccinated pigs was assayed for PRRSV-specific antibodies with IDEXX HerdCheck ELISA kit. 
The threshold for seroconvertion was set at a sample-to-positive (s/p) ratio of 0.4 according to 
manufacturers’ instructions. (C-E) Serum samples were titrated individually in MARC-145 cells 
for the levels of anti-PRRSV neutralizing antibodies 28 days post vaccination (DPV) or 14 days 
post challenge (DPC) determined as the highest dilution that inhibited CPE. Data are shown as 
mean ± SEM (n= 5). Bracketed groups were compared and ** denotes p <0.01. 
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Figure 3 
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Figure 3. Pigs vaccinated with MLV+H9e have increased PRRSV-specific IFN-γ, IL-4, IL-8 
and reduced IL-10 cytokine secretion.  Cytokine expression profiles in the sera of pigs 7 days 
post challenge (DPC) were examined by quantitative ELISA, (A) IFN-γ (B) TNF-α (C) IL-4 and 
(D) IL-8. (E) IL-10 concentrations in serum samples and supernatants of PBMCs and lung 
MNCs which were collected at necropsy (15 DPC) and restimulated with corresponding PRRSV 
strains.  Bracketed groups were compared and * denotes p <0.05, ** denotes p <0.01, and NS=no 
difference. 
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Figure 4 
 
 
Figure 4. Pigs vaccinated with MLV+H9e have decreased T-regulatory and increased 
Th/memory lymphocyte subpopulations. Whole blood was collected and stained for CD4, 
CD8, FoxP3, and CD25. (A) Shown are the percentages of T-reg cells that were triple-positive 
for CD4/FoxP3/CD25 28 days post vaccination (DPV) and (C) 14 days post challenge (DPC). (B) 
Also shown are the percentages of Th/memory cells that were double-positive for CD4/CD8 on 
28 DPV and (D) on 14 DPC. Data is shown as mean ± SEM (n=5). Bracketed groups were 
compared and * denotes p <0.05, ** denotes p <0.01, and NS=no difference. 
